Xiamen Humanity Hospital
The average astrocytoma treatment cost in China typically includes surgical options like craniotomy, which runs from $22,500 to $44,000. For targeted non-invasive care, stereotaxic radiosurgery ranges from $8,500 to $15,800. Total expenses depend on the tumor grade, hospital classification, and required chemotherapy cycles. Patients can achieve 65% to 85% savings compared to the US. Top medical destinations include Beijing, Shanghai, and Guangzhou.
Typical Astrocytoma Treatment Costs in China
Bookimed Expert Insight: For complex neuro-oncology cases, tertiary hospitals like Xiamen Humanity Hospital offer advanced infrastructure including 47 specialized departments. Patients seeking cutting-edge protocols may benefit from clinics accredited for Phase I–IV drug trials. For high-precision radiotherapy, experts like Dr. Liu Shi Xin provide specialized experience in VMAT and SBRT technologies. These high-volume centers manage over 1,000,000 patients annually, balancing innovative clinical trials with established surgical care.
| China | Turkey | Austria | |
| Stereotaxic radiosurgery | from $8,500 | from $4,500 | from $17,000 |
| Radiation therapy for colorectal cancer | from $11,500 | from $3,250 | from $12,000 |
| Craniotomy | from $22,500 | from $6,500 | from $20,000 |
| Chemotherapy for breast cancer | from $14,800 | from $1,200 | from $15,000 |
| Halcyon | - | from $5,400 | - |
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
An astrocytoma is a brain or spinal cord tumor developing from star-shaped cells called astrocytes. The World Health Organization (WHO) classifies these into four grades. Grade 1 and 2 tumors grow slowly. Grade 3 and 4 tumors are aggressive and spread rapidly into tissue.
Bookimed Expert Insight: Chinese oncology centers like Xiamen Humanity Hospital manage over 1,000,000 patients annually. They use advanced techniques like SBRT and Oncothermia for complex cases. Large patient volumes often lead to high proficiency in navigating eloquent brain regions. Confirm if your center offers IMRT or VMAT technology. These systems allow radiation to spare healthy brain tissue more effectively.
Patient Consensus: Patients emphasize that successful surgery means balancing tumor removal with the preservation of speech and movement. Many travelers recommend getting a pathology report that includes molecular markers like IDH status before starting chemo.
Seeking a second opinion on an astrocytoma pathology report is highly recommended before starting treatment. Experts emphasize that brain tumor classification is complex. A specialist review confirms molecular markers like IDH mutations. It ensures you receive the correct grade for personalized care.
Bookimed Expert Insight: High-volume Chinese centers like Xiamen Humanity Hospital serve 1,000,000 patients annually. Large institutions often have accredited labs for phase I-IV drug trials. This scale usually indicates deeper experience with the complex molecular testing needed for astrocytoma. Always verify if a facility has specific clinical trial accreditations for your tumor subtype.
Patient Consensus: Patients note a second review is worth double-checking because glioma diagnosis is technically tricky. They emphasize that modern treatment decisions depend heavily on molecular details rather than just microscopic views.
Beijing Tiantan Hospital and Huashan Hospital are the primary centers for astrocytoma surgery in China. These facilities utilize intraoperative MRI and fluorescence-guided resection for complex gliomas. Leading institutions maintain specialized neuro-oncology multidisciplinary teams and perform thousands of successful brain tumor resections annually.
Bookimed Expert Insight: Xiamen Humanity Hospital stands out as a tertiary center serving 1,000,000 patients yearly with 460 doctors. For astrocytoma patients specifically, the presence of Dr. Liu Shi Xin is a major factor. He holds the National Famous Doctor award and serves as Vice Chairman of the Radiation Oncology Branch. His expertise in precision radiotherapy like IMRT and VMAT is essential for managing high-grade astrocytomas after surgery.
Patient Consensus: Patients emphasize finding surgeons who specifically focus on gliomas rather than general neurosurgery. They note that coordinating pathology and radiation in one location prevents dangerous treatment delays.
Chinese hospitals employ advanced neurosurgical systems like the Remebot and Tianji robotics for high-precision tumor resections. These platforms utilize AI-driven navigation and multispectral tracking to achieve 0.1mm accuracy. Institutions like Xiamen Humanity Hospital provide comprehensive neuro-oncology care within tertiary facilities serving 1,000,000 patients annually.
Bookimed Expert Insight: While many focus on robotics, the true differentiator in Chinese neuro-oncology is the integration of massive patient volumes with domestic innovation. Xiamen Humanity Hospital alone manages 1,000,000 patients every year. This high volume allows surgeons like Dr. Liu Shi Xin to master specialized techniques like VMAT and SBRT for complex tumors much faster than in lower-volume regional centers.
Patient Consensus: Patients emphasize that molecular profiling for IDH mutations and MGMT status is now essential for modern astrocytoma treatment. They note that choosing a surgeon who performs high annual volumes of glioma resections is more critical than the specific robotic brand used.
Chinese neuro-oncology centers offer specialized radiation therapies including proton beam therapy, carbon ion radiotherapy, and boron neutron capture therapy. These facilities use precision technologies like Intensity-Modulated Radiation Therapy and stereotactic radiosurgery to destroy tumor cells while preserving healthy brain tissue and neurocognitive function.
Bookimed Expert Insight: Leadership in Chinese radiation oncology is concentrated in specialists with significant academic influence. Professor Liu Shi Xin at Xiamen Humanity Hospital serves as Vice Chairman of the Particle Therapy Professional Committee. This institutional link suggests that academic tertiary centers in China integrate particle therapy research directly into clinical practice for complex brain tumors.
Patient Consensus: Patients emphasize the need to ask how a radiation plan protects the hippocampus and optic nerves. They note that specialized centers are preferred for younger patients to reduce long-term side effects.
Temozolomide is widely available in China for treating high-grade astrocytoma. The drug has been on the market for over 20 years. Patients can access both imported brand-name Temodar and domestic generics. Chinese oncologists follow the global Stupp protocol standard for malignant gliomas.
Bookimed Expert Insight: While Temozolomide is common, hospital specialization matters for drug access. Centers like Xiamen Humanity Hospital manage 1,000,000 patients annually and possess infrastructure for drug trials. Large-scale tertiary hospitals are more likely to have consistent stock of both imported and domestic versions compared to smaller clinics.
Patient Consensus: Patients suggest asking for the generic name instead of specific brands to ensure availability. They also emphasize confirming if the hospital can dispense the medication directly to simplify the logistics of each cycle.
China integrates Traditional Chinese Medicine (TCM) as a supportive, non-primary therapy for astrocytoma. Medical teams use it alongside surgery, radiation, and chemotherapy. The focus remains on easing treatment side effects. This approach helps boost immune function and patient comfort during recovery phases.
Bookimed Expert Insight: TCM integration is built into the hospital culture at major institutions like Xiamen Humanity Hospital. This center handles 1,000,000 patients annually and performs complex drug trials. Expert oncologists like Dr. Liu Shi Xin work in facilities that combine standard radiation like VMAT with supportive care. This indicates that high-volume Chinese hospitals prioritize a unified, medical-grade approach over separate alternative clinics.
Patient Consensus: Patients note that TCM provides emotional reassurance when prognosis is uncertain. They emphasize using it only as an add-on and never delaying surgery for herbal treatments.